Search:

Instructions to Authors: Gene Therapy & Molecular Biology


ISSN print:1529 9120; ISSN on-line: 1543-9143

Scope

Gene Therapy & Molecular Biology (www.gtmb.org) embraces all aspects of the field for which it is named after. It is the only journal that does not apply any charges to authors and is an open access without subscription passwords to all audiences.

The scope of GTMB is to rapidly publish original and in-depth review articles on cancer embracing all fields from molecular mechanisms to results on clinical trials. Articles (both invited and submitted) review or report novel findings of importance on gene transfer, immunotherapy, signaling, chromatin, drug delivery, new technologies in drug discovery and a number of other subjects. To make the publication attractive, authors are encouraged to include color figures.

Type of articles

Both review articles and original research articles will be considered. Original research articles should contain a generous introduction in addition to experimental data. The articles contain information important to a general audience as the volume is addressed also to researches outside the field. There is no limit on the length of the articles provided that the subject is interesting to a general audience and covers exhaustively a field. The typical length of each manuscript is 12-60 manuscript pages (approximately 4-20 printed pages) plus Figures and Tables.

Authors will receive a PDF format of their article via email so that they can upload it in their personal website or to distribute freely to colleagues as also the accepted manuscript will be available for everyone to download from our website. Furthermore, authors are also entitled to use Figures from their work originally published in GTMB in review articles for other journals by simply citing the original source.

Sections of the manuscript

Each manuscript should have a Title, Authors, Affiliation, Corresponding Author (with Tel, Fax, and E-mail), Summary, and Introduction; review articles are subdivided into headings I, II, III, etc. (starting with I. Introduction) and subdivided into A, B, C, etc. You can further subdivide into 1, 2, 3, etc. Research articles are divided into Summary; I. Introduction; II. Materials and Methods; III. Results IV Discussion; Acknowledgments and References. Please include in your text citations the name of authors and year in parenthesis; for three or more authors use: (name of first author et al, with year); for two authors please use both names. Please delete hidden text for references. In the reference list, please, type references with year and Journal in boldface and provide full title of the article such as:

Buschle M, Schmidt W, Berger M, Schaffner G, Kurzbauer R, Killisch I, Tiedemann J-K, Trska B, Kirlappos H, Mechtler K, Schilcher F, Gabler C, and Birnstiel ML (1998) Chemically defined, cell-free cancer vaccines: use of tumor antigen-derived peptides or polyepitope proteins for vaccination. Gene Ther Mol Biol 1, 309-321.

Please use Microsoft Word, font “Times” (Mac users) or “Times New Roman” (PC users) and insert Greek or other characters using the “Insert/Symbol” function in the Microsoft Word rather than simple conversion to font “Symbol”. Please boldface Figure 1, 2, 3 etc. as well as Table 1, 2, etc. throughout the text. Please provide the highest quality of prints of your Figures; whenever possible, please provide in addition an electronic version of your figures (optional).

Corresponding authors are kindly requested to provide a color (or black/white) head photo (preferably 4x5 cm or any size), or a group photo of the authors, as we shall include these in the publication.

Submission and reviewing

Peer reviewing is completed by members of the Editorial Board and external referees. Please suggest 2-3 reviewers providing their electronic addresses, mailing addresses and telephone/ fax numbers. Authors are being sent page proofs.

Reviewing is completed within 2-3 weeks from receiving the manuscript. Articles accepted without revisions (i.e., review articles) will be published online (www.cancer-therapy.org) in approximately 1 month following submission. Please submit an electronic version of full text and figures preferably in jpeg format. The electronic version of the figures will be used for the rapid reviewing process.

Citation in MedLine

If you have NIH funded research program your full article published in Gene Therapy & Molecular Biology will appear on PubMed as full article freely accessible.
Articles accepted for publication by Gene Therapy & Molecular Biology can be included in MedLine (PubMed) as full articles upon the request of authors provided that the authors have completed their published work under a government grant by NIH (or EU/Japan government grant). If this is your case, please consult the NIH Manuscript Submission System http:// www.nihms.nih.gov/.

Contribute your Article to GTMB

Editorial Office

Teni Boulikas, Ph.D.

Afxentiou 7
Athens 17455 Greece
Tel/Fax: +30-210-985-8453


GTMB Editorial Office:

Afxendiou 7, Alimos Athens, Greece
email: info@gtmb.org

© Gene Therapy Press 1997-2013 fonts

Home | About | www.replica-watch.cn Editorial Board Members | Cancer Therapy Journal | Scroll to Top


| Volume 1-1998 | | Volume 2-1998 | | Volume 3-1999 | | Volume 4-1999 | | Volume 5-2000 | | Volume 6-2001 | | Volume 7-2002 | | Volume 8-2004 | | Volume 9-2005 | | Volume 10-2006 | | Volume 11-2007 | | Volume 12-2008 | | Volume 13-2009 | | Volume 14-2012 | | Volume 15-2013 | | Volume 16-2014 |


© 2013 NB